HNF1A-MODY is one of the most common subtypes of the Maturity Onset Diabetes of the Young (MODY) (McDonald and Ellard 2013) . MODY was defined as monogenic form of diabetes with an autosomal dominant inheritance that occurs before the age of 25 years due to a defect in the function of B-cells (Fajans et al. 2001) . The subtypes of MODY traditionally include mutations of the genes ABCC8, CEL, GCK, HNF1A, HNF1B, HNF4A, INS, KCNJ11, NEUROD1, PDX1, BLK, KLF11 and PAX4 but the last three genes are discussed (Plengvidhya et al. 2007; Borowiec et al. 2009; Fernandez-Zapico et al. 2009; Thanabalasingham and Owen 2011) . Genes APPL1 (MODY14), PCBD1 and RFX6 are newly associated with MODY (Schwitzgebel 2014; Simaite et al. 2014; Prudente et al. 2015; Vaxillaire and Froguel 2016; Kherra et al. 2017) . Population prevalence of MODY is 50-100 per million . Population prevalence of HNF1A-MODY ranges from 0,0066% (in Croatia; Pavic et al. 2018 ) to 3,6% (in UK; Shields and Colclough. 2017) . HNF1A-MODY is caused by the mutations in the HNF1A gene coding the transcription factor -hepatocyte nuclear factor 1 alpha (HNF1α). HNF1A-MODY is nonketotic diabetes with onset during childhood, adolescence, or early adulthood, progressive character of hyperglycemia with a high risk for chronic microvascular diabetes complications. The clinical management of HNF1A-MODY individuals differs from people with the most prevalent diabetes types, Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D). Nevertheless, majority of the individuals with HNF1A-MODY remain misclassified as T1D or T2D. In our review, we focus on the genetic background of HNF1A-MODY, DNA analysis of the HNF1A mutations, clinical diagnostics and treatment strategies.
Genetic background
HNF1A gene. HNF1A-MODY is caused by mutations in the HNF1A gene, which is located on the chromosome 12 (NC_000012.12) in the region 12q24.2. It is oriented on the plus strand (Bach et al. 1990; Szpirer et al. 1994; Scherer et al. 2006) . Reference HNF1A genome sequence is NG_011731.2. The exact genomic position varies depending on genome assembly version, chr12:121,41,549-121,442,315 (30,767 bp) in GRCh37/hg19 assembly and chr12: 120,973,746-121,004,512 (30, 767 bp) in GRCh38/hg38 assembly (O'Leary et al. 2016) .
Three HNF1A transcriptional isoforms (isoform A, B and C) were described to be generated from the same promoter by alternative splicing and different polyadenylation. The longest isoform is HNF1A A (10 exons), shorter is HNF1A B (7 exons) and the shortest is HNF1A C (6 exons) (Harries et al. 2006; Bellanne-Chantelot et al. 2008) . Harries et al. (2006) demonstrated tissue specific expression levels of the HNF1A isoforms by real-time PCR. Isoform A was mostly transcribed in the hepatocytes, kidney and (Vaxillaire et al. 1999; Ryffel 2001; Sneha et al. 2017) . Purple numbers represent amino acids which are phosphorylated. Dashed line defines that NM_000545.5 (the older version of NM_000545.6) has shorter 5´UTR and NM_001306179.1 has longer 5´ part of exon 9 compared to other HNF1A transcripts.
fetal pancreas and less in adult pancreas and pancreatic islets. HNF1A B transcripts were predominant in adult pancreas and islets but less in liver and kidney. HNF1A C displayed the lowest expression levels in these tissues and it was measured mostly in adult pancreas and islets than in liver or kidney. They reported that HNF1A (A) isoform has 5-fold lower activity than HNF1A (B) and HNF1A (C). These discoveries supported an idea that mRNA processing resulting in expression of multiple isoforms depends on the tissue and the stage of development. However, based on National Center for Biotechnology Information (NCBI) database, only 2 HNF1A transcript variants (1 and 2, both containing 10 exons) are registered with unique index and marked as reference sequences (Figure 1 ). NM_001306179.1 represents the longer HNF1A transcript (3438 bp) with coding sequence (CDS) spanning 202-2118 bp and translated to the longer HNF1α protein labelled as NP_001293108.1 (638 aa). The shorter HNF1A isoform 2 is a transcript using an alternate in-frame acceptor splice site of exon 9. The latest version, NM_000545.6, represents processed mRNA sequence (3417 bp) with CDS spanning 202-2097 bp and it is translated to the shorter protein isoform defined as NP_00536.5 (631 aa) (Geer et al. 2009 ). The Locus Reference Genome (LRG) database that curates stable reference sequences used for reporting of DNA variants with clinical use (Dalgleish et al. 2010) , includes the reference sequence for HNF1A LRG_522 that is based on the reference sequence NM_00545.5. This is the older version of NM_00545.6 and differs only in the 5´UTR (Figure 1) . HNF1α protein. Hepatocyte nuclear factor 1α (HNF1α or HNF1A) is a tissue specific transcription factor. The protein contains 3 domains (Figure 1 ). An N-terminal dimerization domain (residues 1-32) forms a four-helix bundle where two α-helices are separated by a turn and that allows the formation of homodimers (Rose et al. 2000b; Narayana et al. 2001) .
HNF1α binds to the inverted palindrome 5'-GTTAATNATTAAC-3' as a homodimer via bipartite DNA-binding domain (DBD) which is formed as a helix-turn-helix structure. (Rose et al. 2000a; . The DBD domain includes two POUsub-domains, POUs (specific domain, amino acids 82-172) and POU H (homeodomain, amino acids 198-281) (Vaxillaire et al. 1999; Ryffel 2001 ). Other literature presents slightly different amino acid positions of DBD (82-174 aa for POUs and 197-287 aa for POU H domain) (Sneha et al. 2017) . POUs is an integral part of HNF1α that helps in maintaining the stability of the protein, whereas the POU H domain acts as a crucial interface initiating the interaction between the protein and DNA (Cleary et al. 1997; Harries et al. 2006) .
Nuclear localization signal (NLS) is not exactly specified, but there are three potential regions based on their highly similarity to consensus NLSs. One potential region is within the POUs domain (residues 158-171) and two potential regions are within the POU H domain (residues 197-205 or 271-282) Bjorkhaug et al. 2003) .
The transactivation domain is at the C-terminus (residues 282-631) (Baumhueter et al. 1990; Harries et al. 2006) . HNF1α physically interacts with histone acetyltransferases (HATs) such as CREB-binding protein (CBP), P300/CBP-associated factor (P/CAF) or steroid receptor coactivator-1 (Src-1) and small GTPase receptor-associated coactivator 3 (RAC3) and they can interact with each other or bind independently to different HNF1α functional domains and synergistically increase HNF1α-mediated transactivation (Soutoglou et al. 2000) . However, online protein-protein interaction (PPI) databases present many more HNF1α interaction partners and each differs based on information sources they use. STRING database present 26 HNF1α interaction partners (Figure 2 ). This database groups known and predicted PPI including direct (physical) and indirect (functional) associations. They stem from computational prediction, from knowledge transfer between organisms, and from interactions aggregated from other (primary) databases (Szklarczyk et al. 2017) . GPS-Prot database shows 54 proteins involved in HNF1α transcriptional network ( Figure 3 , Table 1 ). GPS-Prot links unique scored human PPI from major curated databases (Biogrid, MINT, IntACT, DIP, HPRD, MIPS) and Curated Human Complexes (Fahey et al. 2011) . Since STRING and GPS-Prot are not focused on certain human tissue, IID (Integration Interactions Database) provides tissue-specific PPIs of human. This database shows 56 HNF1α interaction partners in human pancreas (Table 1) . IID consist of experimentally detected PPIs (from BioGRID, IntAct, I2D, MINT, InnateDB, DIP, HPRD, BIND and BCI databases), orthologous protein-protein interactions, and high-confidence computationally predicted PPIs from recent studies (Kotlyar et al. 2016) .
Pathogenesis
HNF1α physiology. HNF1α plays an important role during embryonic development as it affects intestinal epithelial cell growth and cell lineage differentia-tion (D'Angelo et al. 2010; Lussier et al. 2010 ). HNF1α expression was proven also in the adult pancreas, gut, liver and kidney (Harries et al. 2006) . Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics revealed various levels of HNF1A expression in several human tissues (Figure 4) (Fagerberg et al. 2014) . HNF1α binds to at least 222 target genes in the human liver and at least 106 target genes in human pancreatic islets (Odom et al. 2004) .
It is also the transcription regulator of angiotensin-converting enzyme 2 which can be involved in mitochondrial metabolism (Shi et al. 2018) . In addition, HNF1α is the transcriptional regulator of bile acid transporters in the intestine and kidneys thus is important in HDL metabolism (Shih et al. 2001a) .
HNF1α helps to promote the expression of organic cation transporter 1 (OCT1) in the liver which is responsible for hepatic uptake of small, hydrophilic, positively charged organic molecules (Koepsell et al. 2007) . Genetic variations in HNF1α may change OCT1 expression and affect the liver uptake and drug metabolism of OCT1 substrates such as metformin, tropisetron, ondansetron. tramadol and morphine (Shu et al. 2007; Tzvetkov et al. 2011 Tzvetkov et al. , 2012 O'Brien et al. 2013) .
HNF1α directly regulates the expression of low afinity/high capacity glucose cotransporter (SGLT2) which is responsible for renal reabsorbtion of glucose (Pontoglio, 2000) . HNF1α regulates also the tran- Figure 2 . 25 HNF1α protein interaction partners (STRING database). Nodes -each node represents all the splice isoforms produced by a single, protein-coding gene locus. Empty nodes represent proteins of unknown 3D structure and filled nodes represent proteins with known or predicted 3D structure. This interaction network is not focused on any human tissue. Lines -every line color represents different manner of the protein interaction. Light blue -from curated databases. Purple -experimentally determined. Green -predicted interaction based on gene neighborhood. Red -predicted interaction based on gene fusion. Dark blue -predicted interaction based on gene co-occurrence (i.e. phylogenetic distribution of protein orthologs in a human). Yellow -automated textmining of the scientific literature. Black -co-expression. White -protein homology. Modified by (Szklarczyk et al. 2017) . Table 1 ) (Fahey et al. 2011) . (Geer et al. 2009; Fagerberg et al. 2014) . (Fahey et al. 2011; Kotlyar et al. 2016 ).
scription of acute phase proteins involved in inflammation, such as fibrinogen, C-reactive protein (CRP), and interleukin 1 receptor (Armendariz and Krauss 2009). Significantly lower levels of HNF1α protein were observed in pancreatic tumors and hepatocellular adenomas than in normal adjacent tissues (Bluteau et al. 2002; Luo et al. 2015) , so HNF-1α might be a tumor suppressor protein, too.
More detailed information about HNF1α function in different tissues is summarized in Table 2 . In addition, Gene Ontology (GO) Consortium provide experimentally-supported GO annotations accompanied with web access and analytical tools that use the GO knowledgebase (Carbon et al. 2009; Kohler et al. 2017 ). GO database shows 29 different ontologies determining the biological processes related to HNF1α protein (Table 3) .
Transcriptional network. The development and function of adult liver, pancreatic islets or kidney is not regulated by HNF1α alone ( Figure 5 , Table 4 ). HNF1α is co-expressed with other transcription factors, e.g. HNF1β, HNF4α and HNF6 (Stoffers et al. 1997; Edlund 1998; Shih and Stoffel 2001; Nammo et al. 2008; De Vas et al. 2015) . Together with HNF3 (hepatocyte nuclear factor 3), they constitute a functional network regulating the expression of different tissue genes that contain promoter or enhancer DNA sites for these HNFs (Shih et al. 2001b; Costa et al. 2003; Jacquemin et al. 2003; Lau et al. 2018) . Interconnection of HNF transcription factors was experimentally supported by HNF1A-null mice which pancreas displays decreased expression of HNF4A, HNF4G (HNF4γ) and HNF3 genes Shih et al. 2001b ). In the pancreas and liver, HNF1α and HNF4α make transcriptional loop ( Figure 5C ) (Kuo et al. 1992; Kritis et al. 1993; Bulla and Fournier 1994; Gragnoli et al. 1997; Godart et al. 2000; Li et al. 2000; Wang et al. 2000; Eeckhoute et al. 2004 ). Haploinsufficiency of either HNF1α or HNF4α alters bistable transcriptional cascade (Ferrer 2002) . Transcription hierarchy in B-cells has unique properties since HNF1A mutations can cause B-cell dysfunction while the other tissues expressing HNF1A are not damaged (Byrne et al. 1996; Froguel and Velho 1999) .
HNF1α pathophysiology. Mutated HNF1α may alter the gene expression cascade which may alter the (B) HNF regulatory network in liver. HNF3α, HNF3β and GATA4 regulate initial hepatic specification. HNF3β self-regulate its own expression. In adult liver, HNF6 positively regulates expression of HNF1β and HNF4α from the both promoters, P1 and P2. HNF1β regulates the expression of HNF1α and P1-HNF4α and P2-HNF4α. HNF1α regulates expression of P1-HNF4α and P2-HNF4α but only HNF4α expressed from P2 regulates HNF1α. HNF4α expressed P1 promoter inhibits expression of HNF4α from P2 promoter. (C) HNF regulatory network in the pancreas. In developing pancreas, HNF1β positively regulates the expression of HNF6 in pancreatic precursor cells. HNF6 activates the onset expression of PDX1 involved in pancreatic specification as well as expression of NGN3 involved in pancreatic endocrine differentiation. In adult pancreatic B-cells, PDX1 is activator of P2-HNF4α expression (Shih and Stoffel 2001) . HNF6 regulates also expression of HNF3β. HNF1α regulates transcription of P2-driven HNF4α whereas HNF4α AF-2 and DBD domains regulate HNF1α expression. Cofactor p300 enhances expression of HNF1α. HNF1α regulates also the expression of HNF4γ and HNF3γ. In the other literature, HNF3α can be named as FOXA1, HNF3β as FOXA2, HNF3γ as FOXA3, HNF6 as OC1, PDX1 as IPF1 and NGN3 as Neurogenin 3. Modified from Lau et al. (2018) . complications. Furthermore, an intergenic variant rs2650000, near the gene HNF1A, may influence the levels of LDL-cholesterol and C-reactive protein (Kathiresan et al. 2009; Sabatti et al. 2009 ). Gene promoter of the protein C acts as a binding site for HNF1α and disruption of this promoter leads to hereditary thrombophilia, a predisposition of an inappropriate clots forming (Berg et al. 1994 ).
The latest study revealed that MODY3 and T2D are risk factors for pancreatic cancer (Naqvi et al. 2018) . Mutations in the HNF1A gene are connected not just with pancreatic but also with hepatal tumors and renal tumors (Bluteau et al. 2002; Rebouissou et al. 2005; Jeannot et al. 2010; Pierce and Ahsan 2011) . In addition, HNF1A antisense RNA 1 (HNF1A-AS1) is transcribed in the opposite transcription direction from HNF1A gene as 2.455 bp long non-coding RNA (lncRNA) (Chambers et al. 2011 ). Deregulation of HNF1A-AS1 participates in esophageal adenocarcinoma (Yang et al. 2014 ) and lung adenocarcinoma (Wu et al. 2015) . This is a strong evidence that HNF1α has a tumor suppressor function (Hoskins et al. 2014) . Genome Wide Association Studies (GWAS) from 2017 have linked HNF1A gene with 19 different human diseases or biochemical traits (Table 5 ) (MacArthur et al. 2017 ).
Genetics of HNF1A-MODY
Variants in HNF1A gene. MODY3 is a monogenic disease with autosomal dominant inheritance due to HNF1α haploinsufficiency. HNF1A is a polymorphous gene without specified mutation hot-spot. Up to date (November 2018), 380 HNF1A unique DNA variants were recorded in Leiden Open-source Variation Database (LOVD) (Fokkema et al. 2011) . Anyway, the most extensive publication summarizing HNF1A pancreatic development (Naqvi et al. 2018) . Secretion of insulin, secretory response to nutrients, decreased proliferation of B-cells, and abnormal structure of Langerhans islets occur when production of HNF1α protein is insufficient. Impaired B-cell glucose sensing is probably the result of reduced aerobic glycolysis and mitochondrial metabolism (Byrne et al. 1996; Dukes et al. 1998; Pontoglio et al. 1998 ). Low ATP concentration in B-cells disturbs insulin secretion and leads to HNF1A-MODY diabetes (Vesterhus et al. 2008; Sur and Taipale 2016) . In kidneys, HNF1α is involved in the reuptake of glucose from the glomerular filtrate (Pontoglio et al. 2000) . In the case of HNF1A mutation, uptake is less effective and glucose remains at higher concentrations in urine despite normal glycaemia (i.e. it causes reduced kidney threshold for glucose). Glycosuria usually precedes the B-cell insulin secretion defect for several years (Ellard and Colclough 2006) . There is an evident relationship between certain HNF1A variants and T2D risk. This relation can vary among populations. An association of the rare HNF1α variant E508K with T2D was demonstrated in Mexican population (Estrada et al. 2014) . In Canadian Oji-Cre population, G319S is connected with an early-onset T2D (Hegele et al. 1999) . Although HNF1α polymorphisms I27L and A98V do not influence the function of pancreatic B-cells, they may be associated with insulin resistance and HDL cholesterol levels (Chiu et al. 2000; Holmkvist et al. 2006; Gaulton et al. 2015) . In fact, these MODY3 benign variants have mild impact to HNF1α function but their combination can significantly impair HNF1α transactivation activity (Holmkvist et al. 2006; Najmi et al. 2017) . Impaired HNF1α function is, besides the diabetes mellitus, involved in a variety of another health variants states more than 400 different variants, ExAC database presents 894 variants and GnomAD 1231 variants spanning from the HNF1A promoter to 3´UTR region, including missense, frame shift, nonsense, splicing mutations, in-frame amino acid deletions, insertions, duplications or partial and whole-gene deletions (Lek et al. 2016) .
The higher number of mutations were observed in HNF1A exon 2 and exon 4 and the least in exon 5 and exon 10. Mutations in the HNF1A promoter can alter or disrupt the binding site for other transcription factors in the liver and pancreas (Lau et al. 2018 ). These serious consequences may be the reason of the lowest mutation rate (the number of known variants per one nucleotide of a certain domain) at the promoter part of the gene ). The site of promoter mutation influences its activity with different force. For comparison, c.-283A>C weakens the promoter activity to 30% of the wild type but c.-218T>C mutation decreases the activity only to 70% of the wild type (Godart et al. 2000; Lausen et al. 2000) . HNF1α dimerization domain has the highest mutation rate (0.31 per nt) .
Pathogenic mutations in dimerization domain have various impacts to protein function. The potential altered dimerization can result from impaired formation of the complex with crucial dimerization cofactor of hepatocyte nuclear factor 1 (DCoH). DCoH is known also as pterin-4α-carbinolamine dehydratase (PCBD1). Destabilization of this bundle or recessive mutations in PCBD1 gene lead to antibody-negative monogenic diabetes with normal pancreatic morphology and puberty onset Hua et al. 2000; Simaite et al. 2014) . Improper forming of the dimer complex causes impaired binding of HNF1α to its DNA targets and decrease the protein transactivation activity.
Mutations in the DNA-binding homeodomain of the protein attract much attention, as they are related to various human diseases (Chi 2005) . High rates of mutations causing MODY3 were observed at the POU S and POU H regions of HNF1α DBD domain Harries et al. 2006; Colclough et al. 2013 ). However, reduced DNA-binding does not necessary mean reduced transactivation activity, e.g. missense G191D mutation within HNF1α DNA-binding domain decrease DNA-binding activity to 46% of the wild type but transactivation activity remains 88% or even 100% of the wild type (Yang et al. 1999 ). On the other hand, V133M mutation causes relatively small decrease of DNA-binding (to 84% of the wild type) but HNF1α transcription activity is only 50% of the wild type (Galan et al. 2011 ).
HNF1α transactivation domain shows low mutation rate . It is important to note, that results of measurements of transactivation activity can be influenced by the cell lines which were used in the experiment.
Since HNF1α is a transcription factor, its localization to nucleus is crucial. Otherwise, HNF1α cannot reach its gene targets. Despite three HNF1α protein regions 158-171 aa, 197-205 aa, and 271-282 aa are considered to be the nuclear localization regions Bjorkhaug et al. 2003) , several mutations in DBD (R263C) and transactivation domain (P379fs, Q446*, S587fs) are responsible for incorrect or abnormal subcellular localization (Yang et al. 1999; Bjorkhaug et al. 2003) .
Identification and classification of HNF1A variants. New mutations in HNF1A gene are still being Identification of the gene mutations is the first step. The next one is the classification of the variants. The terms mutation and polymorphism may be misleading. To a large extent, "mutation" was considered as a genetic change with prevalence less than 1% in population and/or a genetic change responsible for a certain disease. "Polymorphism" was considered as a genetic change occurring commonly in population and not causing a disease. However, it was shown that some "mutations" have higher prevalence than expected and, vice versa, a rare genetic change can be still just a "polymorphism" . Therefore, based on the instructions of American College of Medical Genetics and Genomics (ACMG), the more appropriate term is "variant" and it can be classified as pathogenic (class 5), likely pathogenic (class 4), variant with uncertain significance (class 3), likely benign (class 2) and benign (class 1) (Richards et al. 2015) . ACGM classification criteria include information from population databases (e.g. Exome Aggregation Consortium, Exome Variant Server, 1000 Genomes, dbSNP, dbVar), disease databases (e.g. ClinVar, OMIM, Human Gene Mutation Database, Human Genome Variation Society, DECIPHER), sequence databases (e.g. NCBI, RefSeqGene, Locus Reference Genomic, MitoMap), tools for in silico analyses (e.g. SIFT, MutationTaster, PolyPhen-2, PROVEAN, CADD, GeneSplicer, Human Splicing Finder, GERP, PhastCons, PhyloP), functional studies, segregation/de novo data and allelic data. Information from these databases and tools are sometimes not sufficient or not available and there are many variants classified as VUS (variant with uncertain significance). In this case, confirmation of a VUS variant in more families and/or more functional studies should be useful for resolving such classification uncertainty. Although Human Gene Mutation Database (HGMD) is considered to be central unified repository of mutations associated with human inherited diseases (Stenson et al. 2014) it should be used with caution. Functional studies of some HNF1A mutations revealed that they have very small impact on HNF1α protein function despite they were described by HGMD as MODY3 pathogenic variants. Even classification of variants to 5 classes is sometimes insufficient, e.g. the HNF1α E508K variant is considered as benign in relation to MODY3 but is linked with significantly fivefold increased risk of T2D (Najmi et al. 2017 ). In addition, Najmi et al. (2017) noticed that only 5 of 11 HNF1A variants impairing protein function were scored as damaging by in silico prediction tools.
Functional studies
In vitro studies. Several functional in vitro studies are used for researching whether certain HNF1A gene mutation has a pathogenic effect to the protein function. Since HNF1α is a transcription factor, these methods include in particular assays analyzing protein nuclear localization, dimerization, DNAbinding, and transactivation activity. To study the subcellular localization, an immunofluorescence assay with a wild type and a mutated protein can be performed (Bjorkhaug et al. 2003) . Altered protein dimerization due to weak HNF1α-cofactor bond can be studied by labelling of DCoH and protein purifying as well as crystallography shows if the HNF1α forms real dimer or just a monomer structure (Rose et al. 2000a) . To determine the effect of a mutation to HNF1α DNA-binding ability, Electrophoretic Mobility Shift Assay (EMSA) can be beneficial. This method can outline also whether the protein binds to DNA as monomer or dimer. HNF1A promoter and transactivation activity is studied mostly by the luciferase assay. The expression levels of HNF1A in different type of tissues can be measured by isolation of mRNA from the target tissue and subsequently reverse transcription (RT) and quantitative (q) PCR as was done by Harries et al. (2006) . With the same method may be confirmed molecular mechanism of pathologic effect of splicing, nonsense and frameshift mutations. With an example of a frameshift mutation c.872dupC, qPCR shown the degradation of such mRNAs with premature STOP codons by nonsensemediated decay.
In vivo studies. All causal genes responsible for monogenic diabetes phenotypes are expressed in the B-cells (Fajans et al. 2001; Shih and Stoffel 2001; Taneera et al. 2014) . In vivo functional studies with human B-cells are limited. Diabetic and non-diabetic mice are widely used as models for functional studies since their genetic variability is the same as in the human populations (Wang et al. 2000) . Neverthe-less, there are differences between mouse and human phenotypes in the presence of the same genotype. HNF1A (+/-) mouse mutant reveals the same phenotype as the wild type (Lee et al. 1998; Boj et al. 2010) . HNF1A-/-mutations are probably incompatible with human life since no homozygous HNF1A mutation has been reported yet. On the contrary, several studies with HNF1A-/-knockout mice were done. Lee et al. (1998) is one of the first study where non-insulindependent diabetes mellitus (NIDDM), Laron dwarfism, impaired liver development and dysfunctional reproductive system developed in HNF1A (-/-) mice within the time range of two weeks after birth (Lee et al. 1998) . Hiraiwa et al. (2001) prepared HNF1A-/-mice deletant of exon 1 by Cre-loxP system. They discovered by Northern Blot analysis that the total number of glucose-6-phosphatase (G6Pase) mRNA in hepatocytes is higher in HNF1A-/-mice than in HNF1A+/-or HNF1A+/+ mice. This supports their hypothesis that high G6Pase expression leading to hepatic glucose overproduction can cause the hyperglycemia (Hiraiwa et al. 2001) . Other studies discovered, that inactivation of mouse HNF1A gene by homologous recombination results in hepatic dysfunction, phenylketonuria and Fanconi syndrome (Pontoglio et al. 1996) as well as decreased expression of the genes encoding glucose transporter 2 (Glut2) and L-pyruvate kinase (pklr) ). Phenotypic differences between human and mice with the same genotype may be explained by the higher expression of the HNF1A gene in rodents than in humans (Harries et al. 2009 ). This might result to higher tolerance of mice to HNF1A damaging and heterozygous mutations ).
Clinics of HNF1A-MODY
General, pathogenic HNF1A mutations are causing the clinical picture of early-onset diabetes and in several individuals diabetes manifests after phase of neonatal transient hyperinsulinemia hypoglycemia. Hyperinsulinemia can be caused by deregulation of the insulin secretion but is less frequent compared to HNF4A mutations (Dusatkova et al. 2011; Stanescu et al. 2012) . During the childhood HNF1A mutation carriers are normoglycemic. However, they could have presence of glucose in the urine (glycosuria) despite normoglycemia (Skupien et al. 2008; Colclough et al. 2013) . Diabetes mellitus manifests usually at the age of 6-25 years with mild osmotic symptoms (polyuria, polydipsia) or as asymptomatic postprandial hyperglycemia without ketosis or ketoacidosis. C-peptide values are lower than in healthy individuals, but higher than for T1D. Fasting glucose is normal at the onset of disease, but there is a marked increase in the oral glucose tolerance test (oGTT) of 2-h glucose versus baseline (>5 mmol/l). Insulin deficiency is progressive, and blood glucose increases gradually with age (0.06 mmol/l/year), with some patients experiencing a higher insulin secretion failure (a decrease in C-peptide concentrations at the limit of measurability) (Stride et al. 2002) . In individuals with an inappropriate treatment and poor collaboration, ketoacidosis could develop over the time (Nyunt et al. 2009; Pruhova et al. 2013) . Chronic microvascular complications are common in individuals with poor diabetes control. The incidence of the chronic microvascular complications is only slightly lower than in T1D and T2D -retinopathy has 47% of patients, 19% nephropathy and 4% neuropathy. Hypertension and ischemic heart disease are at the level of T1D, much rarer than in T2D, but more often than in healthy controls (Steele et al. 2010) .
Clinical criteria of the HNF1A-MODY. Clinical suspicion on HNF1A-MODY is based on the clinical course of the disease. However, clinical features of HNF1A-MODY are variable not just from one family to another but also within the family Corrales et al. 2010; Colclough et al. 2013) and that complicates the diagnostic process. To simplify the assessment of patients' clinical features, several approaches could be used. The first of them are the clinical diagnostic criteria (Ellard et al. 2008 ) which help diabetologists to discriminate patients with HNF1A-MODY from other forms of diabetes:
• Onset of diabetes usually before 25 years (at least one family member).
• Non-insulin-dependent outside the honeymoon phase. The honeymoon period was defined as a period with insulin requirements of less than 0.5 U/kg/day and hemoglobin A1c (HbA1c) level of less or equal to 6% (Abdul-Rasoul et al. 2006 ).
• Family history of diabetes in at least two generations and at least two family members diagnosed in their 20s or 30s, the grandparents often diagnosed after their 45s. They could be diagnosed as T1D or T2D mellitus.
• The absence of pancreatic islet antibodies.
• Glycosuria at blood glucose levels <10 mmol/l.
• Sensitivity to sulfonylureas (Pearson et al. 2000) .
• Several features discriminating HNF1A-MODY from young-onset T2D like no evidence of obesity, insulin resistance or acanthosis nigricans skin disease in family members and other.
Disease onset. While MODY penetration of patients up to 25 years is approximately 63%, it is increased to 93.6% in patients up to 50 years and 98.7% among patients up to 75 years . It was observed, that mutations in different HNF1A gene isoforms may influence the age of disease onset. Patients with HNF1A mutations in exons 8-10 (affecting only isoform A) have later onset MODY3 phenotype than patients with the mutations in exons 1-6 (affecting isoforms A, B and C). Patients carrying missense mutations affecting the transactivation domain have later onset as those with truncating mutations or with missense mutations in the dimerization/DBD domain. On the other hand, when comparing missense and truncating mutations within dimerization/DBD domain, there is no influence of onset (Vaxillaire et al. 1999; Harries et al. 2006; Bellanne-Chantelot et al. 2008; Awa et al. 2011; Colclough et al. 2013 ). In the study of 362 MODY family members, the correlation between the MODY3 onset of child and its exposure to maternal MODY3 diabetes in utero was significant. In case that maternal HNF1A-MODY was diagnosed before the pregnancy, HNF1A-MODY onset of a child was at younger age (Stride et al. 2002) . Family predisposition to obesity or patients´ physical activity may have an additional effect on insulin sensitivity, secretion or demand. Furthermore, MODY3 patients who inherited HNF1A mutation from mother and were exposed to diabetes in utero have earlier disease onset than those who were not. In agreement with this, approximately 50% carriers of HNF1A mutation from father have MODY3 onset after age of 25 years (Klupa et al. 2002) . HNF1A de novo mutations are less frequent (approximately 7% of all HNF1A-MODY patients) (Stanik et al. 2014) .
Beyond the clinical criteria. A big clinical variability of monogenic diabetes considerably complicates the selection of patients for genetic testing. MODY is primarily nonketotic and non-autoimmunity form of diabetes (Fajans et al. 2001) , however, in some individuals with HNF1A-MODY positive B-cell autoantibodies and diabetes ketoacidosis were described (Pruhova et al. 2013; Lebenthal et al. 2018) . The absence of GAD-65 and IA-2 autoantibodies has been proposed as a discriminator between MODY and T1D as the presence of one antibody was established with the 99% sensitivity and 82% specificity for T1D (McDonald et al. 2011a) . Positive pancreatic autoantibodies have been found in several MODY cohorts: 1% of MODY individual tested positive for autoantibodies in British cohort (McDonald et al. 2011a ), 17% in German/Austrian cohort (Schober et al. 2009 ) and 28%, in Czech cohort (Urbanova et al. 2014 ). Moreover, in two studies, different levels of islet cell autoantibodies were observed in HNF1A-MODY patients (Urbanova et al. 2014; Lebenthal et al. 2018) .
MODY calculator was developed to estimate the likelihood of monogenic diabetes for individuals with onset of diabetes before 35 years . Although calculator does not distinct between the different forms of monogenic diabetes, this method is very useful for the selection of diabetes patients for genetic testing (Kherra et al. 2017) .
Role of the biomarkers in the diagnostic process. Several biomarkers for HNF1A-MODY have been considered to support the selection of patients for the genetic testing. Most of the biomarkers are disease specific, i.e. could discriminate HNF1A-MODY from only one other type of diabetes. For example, apolipoprotein M has been suggested as a discriminator between HNF1A-MODY and T1D, but not T2D (Mughal et al. 2013) .
Next, significantly higher ghrelin concentration was measured in HNF1A-MODY and GCK-MODY patients compared to diabetics with T1D or T2D. Ghrelin is a peptide hormone which regulates appetite control and it is encoded by the GHRL gene. HNF1α interacts with the GHRL promoter and suppresses its expression. Despite that it was confirmed also by an animal studies, ghrelin is not sufficient discriminator of diabetes subtypes (Nakazato et al. 2001; Lussier et al. 2010; Brial et al. 2013; Nowak et al. 2015) .
HDL-cholesterol could discriminate between HNF1A-MODY and T2D since HNF1A-MODY patients have higher levels of HDL. Despite of that, HNF1A-MODY patients have similar lipid constituents of HDL and plasma-lipid profiles as people without diabetes . It was observed that also colonic microbiome composition differs among patients with HNF1A-MODY, T2D, and the control group (Mrozinska et al. 2016) .
Cystain C was also studied as a biomarker for HNF1A-MODY but it was shown that this is not a good candidate .
One discriminator between MODY and T1D is measurable C-peptide level in MODY patients. However, C-peptide may be detectable in early T1D, and even in 8% of patients with long-duration T1D what makes the separation of MODY from T1D more difficult. (Oram et al. 2014) .
Human acute phase C-reactive protein (CRP) seems to be the best biomarker for HNF1A-MODY so far. Expression of CRP is regulated in the liver by the HNF1α transcription factor. This attribute of CRP is commonly used for detection of infection and inflammation since its expression rises during that time (Pepys and Hirschfield 2003; Armendariz and Krauss 2009 ). High-sensitivity CRP (hs-CRP) is an assay for detection of small variations in low CRP levels (Soeki and Sata 2016) . Several studies have confirmed that hs-CRP levels were significantly lower in patients with HNF1A-MODY than in patients with HNF4A-MODY, GCK-MODY, T2D and T1D or without diabetes Owen et al. 2010; McDonald et al. 2011b; Shah et al. 2014) .
Some researchers claim that hs-CRP is not useful for distinguishing HNF1A-MODY from (familial) young-onset T2D (Ley et al. 2010; Bellanne-Chantelot et al. 2016; Majidi et al. 2018) . Another limitation of hs-CRP are high CRP levels during the infection ). On the other hand, statin therapy, which is widely used for decreasing the level of total or LDL-cholesterol in T2D, decreases also the CRP levels (Albert et al. 2001 ). In addition, data from independent studies, Pharmacogenomics and Risk of Cardiovascular Disease (PARC) and Cardiovascular Health Study (CHS), pointed out to correlation of plasma CRP concentration and HNF1A common gene variants. SNPs rs1169288 (I27L), rs1169286 (c.326+2159T>C), rs2464196 (S486N), rs1169303 (c.1502-695A>C) and rs1169310 (c.*438G>A) were significantly associated with lower plasma CRP levels (Reiner et al. 2008) . hs-CRP has a big potential to be a cost-effective and helpful biomarker for selecting of HNF1A-MODY patients (Szopa et al. 2019) .
Another biomarker considered for HNF1A-MODY is miRNA-244 -biomarker for B-cell demise (Bacon et al. 2015) . It was found, that miRNA-103 is consistently deregulated in pancreatic and adipose tissue and in serum of patients with T2D (Zhu and Leung 2015) . In the study Bonner et al. (2013) , miRNA-103 and miRNA-244 serum levels were measured in patients with HNF1A-MODY and their MODY-negative family members as well as T2D patients. They have detected higher levels of miRNA-103 and miRNA-244 in serum of HNF1A-MODY patients compared with their MODY-negative family members. Increased levels of serum miRNA-103 may distinguish HNF1A-MODY carriers from T2D patients selected by their HbA1c-levels. miRNA array showed overexpression of miRNA-103, miRNA-244 and miRNA-292-3p also in rat INS-1 cells carrying Pro291fsinsC HNF1A mutation (Bonner et al. 2013 ). However, all of the biomarkers need to be verified in large studies and need to be combined with clinical diagnostic features to make the diagnostic process of HNF1A-MODY more effective.
Epidemiology. HNF1A-MODY is the most common disease in the group of MODY-type diabetes, and is the most common type of the monogenic diabetes in several countries. The certain proportion of HNF1A-MODY among all MODY patients depends on the country. In the Scandinavian countries and Great Britain, HNF1A-MODY is the most common type of monogenic diabetes, while in the Southern Europe, less than 15% of MODY patients have HNF1A-MODY (Eide et al. 2008; Borowiec et al. 2012 ). These proportion variations may be related to geographical location but also to patient search system. HNF1A-MODY is less common among children as the hyperglycemia usually manifests after 10 th year of life. In Poland, where a system for identification of children with monogenic diabetes was developed, HNF1A-MODY accounts for less than 15% of all MODY patients (Borowiec et al. 2012) . A similar situation is in Slovakia and the Czech Republic (Pruhova et al. 2010) . In contrast, in the Scandinavian countries and Great Britain, the DNA analysis for MODY is performed particularly in adults or children treated with low insulin doses.
Therapeutic consequences of the genetically confirmed HNF1A-MODY. Treatment of the HNF1A-MODY depends on the age and HbA1c levels. In case of HbA1c below 6.5% (DCCT), diet without saccharides excess may be temporarily successful. Since the rise of HbA1c, sulfonylurea derivatives may be the useful treatment (Shepherd et al. 2009 ). Patients with HNF1A-MODY are sensitive to sulfonylureas because of its reduced hepatic degradation (Pearson et al. 2000) . This results in higher sulfonylurea plasma levels and longer plasma persistence; thus, low doses of short-acting sulfonylureas are sufficient (Pearson et al. 2000) . Several patients were successfully switched from insulin therapy to sulfonylureas (Shepherd et al. 2003 (Shepherd et al. , 2009 ). Compared to insulin treatment, sulfonylurea derivatives increase endogenous insulin secretion, which allows the body to respond spontaneously to glycemic changes (Shepherd et al. 2009 ). Glycemia is so more stable and diabetes compensation is also improved (Pearson et al. 2000) . In sulfonylurea treatment, low doses should be initiated for the possible occurrence of post-initiation hypoglycemia. Even in patients initially treated with insulin, treatment may be successfully changed to sulfonylureas getting better diabetes control (Bazalova et al. 2010) . However, confirmation of the HNF1A-MODY by DNA analysis prior the therapy change is required. This treatment is usually effective for several decades, but in a case of severe decrease in B-cell insulin production, it may be necessary to switch back to insulin treatment in some patients.
Conclusions
Pathogenic mutations located within HNF1A gene are one of the most common causes of monogenic diabetes. Improper classification of HNF1A-MODY patients as T1D or T2D diabetics based on their clinical manifestation can leads to improper treatment. Bad compensation of HNF1A-MODY may cause microvascular complications. DNA analysis still remains the only way how to definitely confirm the suspicion of HNF1A-MODY. Decision whether the variant is pathogenic or benign is the latest challenge of clinical scientists and doctors. Identification of HNF1A pathogenic variants is highly important not only in terms of a treatment but particularly for determination of genetic risk for descendants of HNF1A-MODY patients.
In Slovakia, the DNA diagnostics of HNF1A gene is available in the DIABGENE Laboratory (diabgene@savba.sk; www.diabgene.sk).
